Perioperative medicine & outcomes
IRON NOF trial: IV iron for anaemic patients with femoral fracture
Primary result · Incidence of blood transfusionResult — go to the resultOdds ratio 1.70 95% CI 0.83–3.47- terminated early
- Terminated early because of jurisdictional changes to more restrictive transfusion practices and changes in consent requirements
Authors' conclusion
In anaemic patients undergoing surgery for hip fracture, i.v. iron did not reduce the overall proportion of patients receiving blood transfusion.
Study context
- Population
- Patients >60 yr with preoperative anaemia undergoing surgery for femoral neck or subtrochanteric fracture, seven Australian hospitals
- Participants
- 143 patients
- Comparison
- IV iron carboxymaltose 1000 mg vs placebo at operation
- i.v. ironn = 70
- Placebon = 73reference
- Primary endpoint
- Blood transfusion use
Methodological detailsphase III, double-blind, placebo-controlled, multicentre
- Phase III
- Double-blind
- Placebo-controlled
- Multicentre
Primary result
Incidence of blood transfusion
Odds ratio
1.70
95% CI 0.83–3.47
P = 0.15
Events by treatment group
Placebo vs IV iron
OR 1.70 (95% CI 0.83–3.47); P = 0.15
As reported in the abstract
Secondary outcomes
| Outcome | Estimate | P value | |
|---|---|---|---|
| Number of blood units transfusedPlacebo vs IV iron · no overall difference in median units | OR 1.52 (95% CI 0.77–3.00) | P = 0.22 | |
| Units of blood transfused, younger patients without major bleeding (subgroup)Placebo vs IV iron | IRR 3.88 (95% CI 1.16–13.0) | P = 0.03 | |
| 0.050.21520Ratio (log scale) |
| Outcome | Placebo | P value |
|---|---|---|
| Hb · 6 weeksIV iron vs Placebo | 108 g L-1 | P = 0.01 |
- Hb: IV iron 116 g L-1
Hospital LOS, rehabilitation duration to discharge, 6-month mortality
- No difference observed
Original publication
IRON NOF trial: IV iron for anaemic patients with femoral fracture. BJA Open. Published 12 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →